Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00540813
Other study ID # BBM-VS-56
Secondary ID
Status Completed
Phase N/A
First received October 5, 2007
Last updated February 22, 2017
Start date October 2007
Est. completion date October 2016

Study information

Verified date February 2017
Source Heart Centre Rotenburg
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to investigate the feasibility of Paclitaxel-eluting PTCA-balloon dilation (SeQuent Please) followed by bare metal stent (Coroflex ) deployment in the main branch (reference diameter: ≥ 2.5 mm and ≤ 3.8 mm, reference diameter of side branch: ≥ 2.0 mm and ≤ 3.5 mm, length of stenoses in either branch ≤ 20 mm) in the treatment of significant (>70%) de-novo-bifurcation stenoses of any Medina classification type in the native left coronary artery as reflected by procedural success and to evaluate the preservation of vessel patency.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date October 2016
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with stable angina pectoris (CCS class 1-3) or with unstable angina pectoris (Braunwald class 1-2, A-C) or documented ischemia or with documented silent ischemia

- Women of childbearing potential may not be pregnant nor have the desire to becoming pregnant during the first year following the study procedure. Hence, patients will be advised to use an adequate birth control method up to and including 6-month follow-up

- Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in following the study protocol

- Patients must agree to undergo the 9-month angiographic follow-up

- Patients must agree to undergo the 3-year clinical follow-up

- Patient is able to verbally acknowledge and understand the associated risks, benefits, and treatment alternatives of this trial. The patients, by providing their informed consent, must agree to these risks and benefits as stated in the patient informed consent document.

Inclusion Criteria: Lesion Related

- De-novo bifurcational native left coronary artery lesion (reference diameter LAD or LCx: 2.5 mm to 3.8 mm, length of stenosis: = 20 mm, reference diameter D1/D2 or OMS1/OMS2: 2.0 mm to 3.5 mm, length of stenosis: = 20 mm)

- Diameter stenosis pre procedure must be either more then 70 % in either one or both branches of the lesion (i.e., bifurcational lesion of any type of the Medina classification) or more then 50 % if ischemia corresponding to the target lesion is documented either by exercise stress ECG, stress echocardiography, scintigraphy, MRT, or suspected based on angina pectoris

- Single or multi-vessel coronary artery disease

Exclusion Criteria:

- Patients with acute (< 24 h) or recent (48 hours) myocardial infarction

- Patients with unstable angina pectoris (Braunwald class 3)

- Patients with severe congestive heart failure

- Patients with severe heart failure NYHA IV

- Patients demonstrating clinical signs of cardiogenic shock at the time of the procedure (systolic blood pressure of less than 80 mmHg requiring inotropic support, IABP, and/or fluid challenge)

- Patients with severe valvular heart disease

- Women who are pregnant or lactating

- Patients with life expectancy of less than five years or factors making clinical follow-up difficult

- Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication is contraindicated

- Patients who had a cerebral stroke < 6 months prior to the procedure

- Patient participates in other clinical trials involving any investigational device or drug

- Untreated hyperthyroidism

- Patient has presence or history of severe renal failure (GFR<30ml/min, "Cockcroft Gault") and is therefore at high risk for angiography associated renal complications. Patient's serum creatinine levels must be documented

- Post transplantation of any organ or immune suppressive medication

- Other disease to jeopardize follow-up (e.g., malignancy)

- Addiction to any drug or to alcohol

- Patients with any type of surgery during the week preceding the interventional procedure.

- Therapy with anticoagulants

Exclusion Criteria: Lesion Related

- Evidence of extensive thrombosis within target vessel before the intervention

- Multilesion percutaneous coronary intervention beside the bifurcation lesion in the left coronary artery (no other intervention is admitted during the same procedure)

- Patients with another coronary stent implanted previously into the target vessel = 15 mm distant to the current lesion, drug eluting stents less than 9 months and bare metal stents or stents with passive coatings less than 3 months before the PEPCAD V BIF

- Target lesion located in any type of coronary bypass (i.e., venous graft, arterial bypass) or graft/native artery connection

- Coronary artery occlusion of any type (e.g., acute or chronic)

- In-stent restenosis

- In-segment restenosis of the native vessel within 4 mm adjacent to the target lesion

Study Design


Related Conditions & MeSH terms


Intervention

Device:
drug eluting balloon
drug eluting balloon bifurcated coronary lesions single arm study

Locations

Country Name City State
Germany F.X.Kleber Berlin
Germany D.G: Mathey Hamburg

Sponsors (3)

Lead Sponsor Collaborator
Heart Centre Rotenburg B. Braun Melsungen AG, Clinical Research Institute Rotenburg a.d.F.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedural success (main branch = 30%, side branch = 50%, TIMI Flow 3) acute
Secondary In-segment late lumen loss at 9 months in either branch 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT05443061 - Subcutaneous Nitroglycerin to Prevent Radial Artery Occlusion in Children N/A
Recruiting NCT05158257 - Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity N/A
Recruiting NCT06006975 - Early Warning of Delayed Cerebral Ischemia
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT02758847 - Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty N/A
Completed NCT02557282 - CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol
Enrolling by invitation NCT02033681 - Optimal Time Delay of Epinephrine Injection With "One-per-mil" Tumescent Solution N/A
Completed NCT01608035 - Sciatic Perineural Versus Stump Catheter for Below Knee Amputation Phase 0
Active, not recruiting NCT01518842 - Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy N/A
Completed NCT01625832 - Effects of Coronary Sinus Occlusion on Myocardial Ischemia (Pilot Study) N/A
Active, not recruiting NCT01281241 - Study on Mechanical and Electrical Alternans N/A
Completed NCT00778323 - Clinical Trial of Remote Preconditioning in Patients Undergoing Cervical Decompression Surgery Phase 1/Phase 2
Completed NCT00371371 - Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI) Phase 1/Phase 2
Terminated NCT00760708 - Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
Not yet recruiting NCT06039748 - Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Completed NCT04879875 - New Method for Real-time Detection of Tissue Ischemia (ISCALERT) N/A
Completed NCT00526474 - Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Phase 3
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A
Completed NCT02910778 - The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males Phase 4
Completed NCT02552498 - Post Occlusive Reactive Hyperemia on Gingiva Assessed by Laser Speckle Contrast Imaging N/A